CERA

Close Menu

Donate

Donate to CERA

Subscribe

Get monthly updates

Clinical trials

Take part in research
Close Close

Science and Research

VELODROME: A Phase IIIb, Global, Multicenter, Randomised, Visual-Assessor-Masked Study of the Efficacy, Safety, and Pharmocokinetics of a 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration

A study of the efficacy, safety, and pharmacokinetics of a 36-week refill regimen for the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.

Overview

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).

  • Principal Investigator
Associate Professor Sanj Wickremasinghe

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.

Read More

Related Pages

Clinical trials

Refer a patient

We welcome referrals from healthcare practitioners of patients who may be suitable for a clinical trial at CERA.

Clinical trials

Register your interest in clinical trials

To express interest in taking part in current or future clinical trials at CERA, please join our online database below. First, here are some important things you need to know.